Complete remission in plasma cell leukaemia
- 1 March 1986
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 62 (3), 525-527
- https://doi.org/10.1111/j.1365-2141.1986.tb02964.x
Abstract
Two patients with primary plasma cell leukaemia who achieved complete remission are reported. They were treated with induction therapy consisting of a multipeptide derivative of sarcolysin, Peptichemio, given intravenously, combined with vincristine and/or prednisone, followed by conventional melphalan-prednisone therapy. 5-7 months following the beginning of therapy, both patients attained a complete remission which lasted 23 and 6 months; second remission was not achieved. Survival from starting therapy was 57 and 16 months respectively. These cases indicate that intravenous alkylating agents can induce a complete remission in plasma cell leukaemia similar to that achieved in other acute leukaemias.This publication has 4 references indexed in Scilit:
- HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMAThe Lancet, 1983
- Primary Plasma Cell LeukaemiaActa Haematologica, 1983
- Leukemic form of immunocytic dyscrasia (plasma cell leukemia)American Journal Of Medicine, 1969